Related Experiment Video
Updated: May 20, 2025
12:18
A Machine Learning Approach to Design an Efficient Selective Screening of Mild Cognitive Impairment
Published on: January 11, 2020
7.4K
[Clinical guidelines «Cognitive disorders in the elderly and senile persons»]
O N Tkacheva1, N N Yahno1, N G Neznanov1
1.
Zhurnal Nevrologii I Psikhiatrii Imeni S.S. Korsakova
|March 24, 2025
Summary
This study outlines clinical guidelines for managing cognitive disorders in elderly and senile individuals. It provides a framework for diagnosis and treatment of age-related cognitive decline.
Area of Science:
- Gerontology
- Neurology
- Psychiatry
Background:
- Cognitive disorders are prevalent in the elderly population.
- Age-related cognitive decline significantly impacts quality of life.
- Senile cognitive impairments require specific clinical management strategies.
Purpose of the Study:
- To establish comprehensive clinical guidelines for cognitive disorders in the elderly.
- To standardize diagnostic approaches for senile cognitive impairments.
- To recommend evidence-based treatment and management protocols.
Main Methods:
- Review of existing literature and clinical studies.
- Consensus development among geriatric specialists and neurologists.
- Formulation of diagnostic criteria and therapeutic recommendations.
Main Results:
- Defined key features of common elderly cognitive disorders.
- Outlined differential diagnostic pathways.
- Provided recommendations for pharmacological and non-pharmacological interventions.
Conclusions:
- Standardized guidelines are crucial for optimal care of elderly patients with cognitive disorders.
- Early diagnosis and tailored interventions can improve outcomes.
- Adherence to these guidelines will enhance clinical practice in geriatrics and neurology.
More Related Videos
Related Concept Videos
01:30Dementia
78
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
78
01:30Cognitive Development During Adulthood
36
Cognitive development continues throughout adulthood, undergoing significant shifts across early, middle, and late stages. Individual transition occurs from adolescent idealism to pragmatic and adaptable thinking in early adulthood. During this period, individuals learn to integrate personal beliefs with the recognition that other perspectives are equally valid. Exposure to the complexities of modern society, diverse experiences, and higher education contribute to this adaptive thought process,...
36
01:26Alzheimer's Disease: Overview
399
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
399
01:30Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists
86
Cognitive enhancers, also known as "smart drugs," are substances used to enhance memory, mental alertness, and concentration. These can be natural or synthetic and improve cognition in conditions like Alzheimer's disease (AD) and other neurodegenerative diseases. Some common examples include caffeine, amphetamines, methylphenidate, modafinil, arecoline, donepezil, vortioxetine, and piracetam. These enhancers work on the principle of synaptic plasticity and altered circuit function.
86
01:22Alzheimer's Disease: Treatment
137
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
137
01:30Negative and Cognitive Symptoms of Schizophrenia
39
Negative symptoms of schizophrenia indicate a reduction or absence of typical behaviors and emotional responses found in healthy individuals, while positive symptoms reflect an excess or distortion of normal functioning.
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
Negative Symptoms
Negative symptoms of schizophrenia manifest as deficits in normal emotional and behavioral functioning, profoundly impacting daily life. Individuals with schizophrenia often display a flat affect, characterized by a near-total absence of emotional expression,...
39